ここから本文です

MediciNova to Conduct Further Analyses of the Data with UCLA

Commenting on the results, Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, stated that the Company will conduct further analyses of the data with UCLA researchers, which will help to better understand how to optimize study design and setting for any future clinical trials in substance dependence. MediciNova will also discuss the results with NIH/NIDA who provided the funding for this trial, the opioid dependence trials and the alcohol dependence trial.

Yuichi added that the Company plans to meet with FDA after it obtains data from the ongoing study of MN-166 in methamphetamine use disorder at Oregon Health & Science University.